News Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Real-time Estimate Cboe BZX 22:37:31 19/08/2026 +03			5-day change	1st Jan Change
551.48 ^USD	+4.41%		+4.44%	+21.11%

08-12	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
08-11	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT

All News

Mentions Relevance

08-12	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
08-11	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
08-11	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
08-10	Vertex Shares Rise as Rival Sionna's Cystic-Fibrosis Trial Fails to Meet Endpoint	DJ
08-10	Sionna scraps genetic disorder drug program after trial setback; shares tank	RE
08-05	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
08-05	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)	PU
08-04	Tranche Update on Vertex Pharmaceuticals Incorporated's Equity Buyback Plan announced on May 19, 2025.	CI
08-04	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT
08-04	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
08-04	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
08-04	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
08-04	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
08-04	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT
08-04	Cantor Fitzgerald Adjusts PT on Vertex Pharmaceuticals to $595 From $590, Maintains Overweight Rating	MT
08-04	Canaccord Genuity Adjusts PT on Vertex Pharmaceuticals to $442 From $436, Maintains Hold Rating	MT
08-04	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
08-04	Vertex Pharmaceuticals Incorporated, Q2 2026 Earnings Call, Aug 03, 2026
08-04	Vertex Pharmaceuticals Bumps Up Fiscal Year Outlook on Growth of Cystic Fibrosis Drugs	DJ
08-03	Vertex: Q2 Earnings Snapshot	AQ
08-03	Vertex Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance	MT
08-03	(VRTX) Vertex Pharmaceuticals Now Expects 2026 Revenue Range $13.1B-$13.2B, vs. FactSet Est of $13.06B	MT
08-03	Vertex raises annual revenue forecast on cystic fibrosis drugs strength	RE
08-03	Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Reports Q2 Revenue $3.33B, vs. FactSet Est of $3.23B	MT
08-03	Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Posts Q2 Adjusted EPS $4.73 per Share, vs. FactSet Est of $4.74	MT